Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $1.7 billion.

  • UNITED THERAPEUTICS's Cash & Equivalents fell 13.76% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 13.76%. This contributed to the annual value of $1.7 billion for FY2024, which is 40.53% up from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Cash & Equivalents stood at $1.7 billion for FY2024, which was up 40.53% from $1.2 billion recorded in FY2023.
  • Over the past 5 years, UNITED THERAPEUTICS's Cash & Equivalents peaked at $1.7 billion during FY2024, and registered a low of $738.7 million during FY2020.
  • In the last 3 years, UNITED THERAPEUTICS's Cash & Equivalents had a median value of $1.2 billion in 2023 and averaged $1.3 billion.
  • Data for UNITED THERAPEUTICS's Cash & Equivalents shows a peak YoY surged of 40.53% (in 2024) over the last 5 years.
  • UNITED THERAPEUTICS's Cash & Equivalents (Yearly) stood at $738.7 million in 2020, then increased by 21.13% to $894.8 million in 2021, then grew by 7.42% to $961.2 million in 2022, then grew by 25.65% to $1.2 billion in 2023, then spiked by 40.53% to $1.7 billion in 2024.